- Home
- DQ vs RCUS Comparison
DQ vs RCUS Comparison
Compare DQ & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- RCUS
- Stock Information
- Founded
- DQ 2006
- RCUS 2015
- Country
- DQ China
- RCUS United States
- Employees
- DQ N/A
- RCUS N/A
- Industry
- DQ Semiconductors
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- RCUS Health Care
- Exchange
- DQ Nasdaq
- RCUS Nasdaq
- Market Cap
- DQ 1.4B
- RCUS 1.4B
- IPO Year
- DQ 2010
- RCUS 2018
- Fundamental
- Price
- DQ $19.22
- RCUS $15.72
- Analyst Decision
- DQ Hold
- RCUS Buy
- Analyst Count
- DQ 5
- RCUS 12
- Target Price
- DQ $20.31
- RCUS $34.50
- AVG Volume (30 Days)
- DQ 2.5M
- RCUS 932.9K
- Earning Date
- DQ 10-30-2024
- RCUS 11-06-2024
- Dividend Yield
- DQ N/A
- RCUS N/A
- EPS Growth
- DQ N/A
- RCUS N/A
- EPS
- DQ N/A
- RCUS N/A
- Revenue
- DQ $1,310,019,000.00
- RCUS $263,000,000.00
- Revenue This Year
- DQ N/A
- RCUS $112.97
- Revenue Next Year
- DQ $47.79
- RCUS N/A
- P/E Ratio
- DQ N/A
- RCUS N/A
- Revenue Growth
- DQ N/A
- RCUS 119.17
- 52 Week Low
- DQ $13.62
- RCUS $13.50
- 52 Week High
- DQ $30.85
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- DQ 42.58
- RCUS 43.78
- Support Level
- DQ $20.50
- RCUS $15.03
- Resistance Level
- DQ $22.31
- RCUS $18.98
- Average True Range (ATR)
- DQ 1.72
- RCUS 1.02
- MACD
- DQ -0.54
- RCUS -0.04
- Stochastic Oscillator
- DQ 0.29
- RCUS 20.07
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.